Yüklüyor......
Does KRAS Testing in Metastatic Colorectal Cancer Impact Overall Survival? A Comparative Effectiveness Study in a Population-Based Sample
PURPOSE: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. PATIENTS A...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Public Library of Science
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4006772/ https://ncbi.nlm.nih.gov/pubmed/24788807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0094977 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|